peritoneal metastasis

Optimizing Treatment Strategies for Gastric Cancer with Positive Peritoneal Cytology or Localized Peritoneal Metastasis

By MedXY 10/22/2026

This article reviews a multicenter study comparing outcomes of different treatment approaches for gastric cancer patients with positive peritoneal cytology (CY1) and/or localized peritoneal metastasis (P1a), highlighting the superior survival with upfront chemotherapy followed by gastrectomy after cytology conversion.

Gastroenterology news Oncology

Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: Phase 3 Trial

By MedXY 06/10/2026

A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.

Gastroenterology news Oncology

Intraperitoneal and Intravenous Paclitaxel Plus S-1 Improves Survival in Gastric Cancer With Peritoneal Metastasis: Phase 3 Trial

By MedXY 05/25/2026

A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.

Gastroenterology news Oncology

Intraperitoneal Chemotherapy for Gastric Cancer: Promising Survival Signals but Very Low‑Certainty Evidence

By MedXY 12/16/2025

A Cochrane review of nine RCTs (829 patients) found low‑certainty signals that intraperitoneal chemotherapy (mainly HIPEC) may improve overall survival in high‑risk and metastatic gastric cancer, but evidence is very uncertain due to bias, imprecision, and limited safety and QOL data.